195 related articles for article (PubMed ID: 34175693)
1. Systemic bevacizumab as adjuvant therapy for recurrent respiratory papillomatosis in children: A series of three pediatric cases and literature review.
Enrique OH; Eloy SH; Adrian TP; Perla V
Am J Otolaryngol; 2021; 42(5):103126. PubMed ID: 34175693
[TBL] [Abstract][Full Text] [Related]
2. Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Institution's Experience.
So RJ; Rayle C; Joo HH; Huang EY; Seiwert TY; Raabe EH; Best SR
Laryngoscope; 2024 Jul; 134(7):3253-3259. PubMed ID: 38525973
[TBL] [Abstract][Full Text] [Related]
3. Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Center Experience of Two Cases.
Bedoya A; Glisinski K; Clarke J; Lind RN; Buckley CE; Shofer S
Am J Case Rep; 2017 Jul; 18():842-846. PubMed ID: 28757601
[TBL] [Abstract][Full Text] [Related]
4. Aggressive recurrent respiratory papillomatosis: A series of five consecutive patients successfully treated with adjuvant intravenous bevacizumab. A single Belgian academic center experience.
Collette F; Lawson G; Hassid S; Delahaut G; Bachy V; Van Der Vorst S; Faugeras L; Gilliaux Q; D'Hondt L
Head Neck; 2023 May; 45(5):1071-1079. PubMed ID: 36840929
[TBL] [Abstract][Full Text] [Related]
5. Systemic bevacizumab for recurrent respiratory papillomatosis: A national survey.
Best SR; Mohr M; Zur KB
Laryngoscope; 2017 Oct; 127(10):2225-2229. PubMed ID: 28657692
[TBL] [Abstract][Full Text] [Related]
6. Recurrent laryngeal papillomatosis: multimodal therapeutic strategies. Literature review and multicentre retrospective study.
Bertino G; Pedretti F; Mauramati S; Filauro M; Vallin A; Mora F; Crosetti E; Succo G; Peretti G; Benazzo M
Acta Otorhinolaryngol Ital; 2023 Apr; 43(Suppl. 1):S111-S122. PubMed ID: 37698108
[TBL] [Abstract][Full Text] [Related]
7. Use of 532-nm pulsed potassium titanyl phosphate laser and adjuvant intralesional bevacizumab for aggressive respiratory papillomatosis in children: initial experience.
Maturo S; Hartnick CJ
Arch Otolaryngol Head Neck Surg; 2010 Jun; 136(6):561-5. PubMed ID: 20566906
[TBL] [Abstract][Full Text] [Related]
8. Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis.
Allen CT; Lee S; Norberg SM; Kovalovsky D; Ye H; Clavijo PE; Hu-Lieskovan S; Schlegel R; Schlom J; Strauss J; Gulley JL; Trepel J; Hinrichs CS
J Immunother Cancer; 2019 May; 7(1):119. PubMed ID: 31053174
[TBL] [Abstract][Full Text] [Related]
9. Squamous Cell Papillomatosis in the Setting of Recurrent Respiratory Papillomatosis.
Bentley PL; Coulter MJ; Nelson BL
Head Neck Pathol; 2019 Jun; 13(2):235-238. PubMed ID: 29594918
[TBL] [Abstract][Full Text] [Related]
10. Systemic bevacizumab for recurrent respiratory papillomatosis.
Baday YI; Ongkasuwan J; Venkatramani R
Int J Pediatr Otorhinolaryngol; 2020 Nov; 138():110352. PubMed ID: 32906078
[TBL] [Abstract][Full Text] [Related]
11. Juvenile recurrent respiratory papillomatosis: still a mystery disease with difficult management.
Stamataki S; Nikolopoulos TP; Korres S; Felekis D; Tzangaroulakis A; Ferekidis E
Head Neck; 2007 Feb; 29(2):155-62. PubMed ID: 17022088
[TBL] [Abstract][Full Text] [Related]
12. Parenteral Bevacizumab for the Treatment of Severe Respiratory Papillomatosis in an Adult Population.
Tkaczuk A; Trivedi S; Mody MD; Steuer CE; Shin DM; Klein AM; Saba NF
Laryngoscope; 2021 Mar; 131(3):E921-E928. PubMed ID: 33107615
[TBL] [Abstract][Full Text] [Related]
13. Use of adjuvant intralesional bevacizumab for aggressive respiratory papillomatosis in children.
Rogers DJ; Ojha S; Maurer R; Hartnick CJ
JAMA Otolaryngol Head Neck Surg; 2013 May; 139(5):496-501. PubMed ID: 23681032
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of bevacizumab and cidofovir treatment in HPV-associated recurrent respiratory papillomatosis - review of the literature.
Jackowska J; Piersiala K; Klimza H; Wierzbicka M
Otolaryngol Pol; 2018 Jun; 72(4):1-8. PubMed ID: 30190442
[TBL] [Abstract][Full Text] [Related]
15. Recurrent laryngeal papillomatosis with oesophageal involvement in a 2 year old boy: successful treatment with the quadrivalent human papillomatosis vaccine.
Mészner Z; Jankovics I; Nagy A; Gerlinger I; Katona G
Int J Pediatr Otorhinolaryngol; 2015 Feb; 79(2):262-6. PubMed ID: 25496821
[TBL] [Abstract][Full Text] [Related]
16. Recurrent respiratory papillomatosis.
Kashima HK; Mounts P; Shah K
Obstet Gynecol Clin North Am; 1996 Sep; 23(3):699-706. PubMed ID: 8869953
[TBL] [Abstract][Full Text] [Related]
17. Clinical Activity of Nivolumab for Human Papilloma Virus-Related Juvenile-Onset Recurrent Respiratory Papillomatosis.
Creelan BC; Ahmad MU; Kaszuba FJ; Khalil FK; Welsh AW; Ozdemirli M; Grant NN; Subramaniam DS
Oncologist; 2019 Jun; 24(6):829-835. PubMed ID: 30842242
[TBL] [Abstract][Full Text] [Related]
18. [Tracheobronchial and pulmonary papillomatosis without involvement of the larynx treated with intravenous Bevacizumab in a child].
Cuestas G; Rodríguez V; Doormann F; Bellia Munzón P; Bellia Munzón G
Arch Argent Pediatr; 2019 Feb; 117(1):e72-e76. PubMed ID: 30652461
[TBL] [Abstract][Full Text] [Related]
19. High-dose sublesional bevacizumab (avastin) for pediatric recurrent respiratory papillomatosis.
Sidell DR; Nassar M; Cotton RT; Zeitels SM; de Alarcon A
Ann Otol Rhinol Laryngol; 2014 Mar; 123(3):214-21. PubMed ID: 24633948
[TBL] [Abstract][Full Text] [Related]
20. Systemic bevacizumab for end-stage juvenile recurrent respiratory papillomas: A case report.
Hamdi O; Dome J; Zalzal G; Preciado D
Int J Pediatr Otorhinolaryngol; 2020 Jan; 128():109706. PubMed ID: 31610441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
